POINT Biopharma Global In... (PNT)
NASDAQ: PNT
· Real-Time Price · USD
12.50
0.02 (0.16%)
At close: Dec 26, 2023, 10:00 PM
POINT Biopharma Global Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 2.79M | 4.87M | 9.46M | 226.58M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | -9.45B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | 2.79M | 4.87M | 9.46B | 226.58M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -29.63M | -31.5M | -22.46M | 191.36M | -24.64M | -24.89M | -16.31M | -14.1M | -17.03M | -8.65M | -5.73M |
Interest Income | n/a | n/a | n/a | n/a | n/a | 509.7K | 47.97K | n/a | n/a | n/a | n/a |
Pretax Income | -23.9M | -26.33M | -16.77M | 194.11M | -23.83M | -24.4M | -16.29M | -14.14M | -17.04M | -8.68M | -5.74M |
Net Income | -24.77M | -25.41M | -16.53M | 163.27M | -24.01M | -24.58M | -16.38M | -14.2M | -17.12M | -8.8M | -5.78M |
Selling & General & Admin | 5.51M | 5.09M | 5.01M | 7.28M | 3.84M | 4.08M | 3.81M | 4.57M | 4.03M | 1.95M | 1.46M |
Research & Development | 26.91M | 31.28M | 26.91M | 27.94M | 20.8M | 20.81M | 12.5M | 9.53M | 13M | 6.7M | 4.27M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 32.42M | 36.36M | 31.92M | 35.22M | 24.64M | 24.89M | 16.31M | 14.1M | 17.03M | 8.65M | 5.73M |
Interest Expense | n/a | n/a | n/a | n/a | 1.05M | 509.7K | 47.97K | 40.25K | 6.18K | 2.86K | 2.8K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 32.42M | 36.36M | 31.92M | 35.22M | 24.64M | 24.89M | 16.31M | 14.1M | 17.03M | 8.65M | 5.73M |
Income Tax Expense | 871.45K | -921.3K | -238.64K | 30.84M | 180.5K | 183.41K | 88.12K | 60.41K | 81.04K | 123.78K | 40.42K |
Shares Outstanding (Basic) | 105.77M | 105.72M | 105.66M | 96.03M | 92.4M | 90.12M | 90.12M | 90.12M | 90.12M | 57.58M | 56.67M |
Shares Outstanding (Diluted) | 105.77M | 105.72M | 105.66M | 96.03M | 92.4M | 90.12M | 90.12M | 90.12M | 90.12M | 57.58M | 56.67M |
EPS (Basic) | -0.23 | -0.24 | -0.16 | 1.73 | -0.26 | -0.27 | -0.18 | -0.16 | -0.19 | -0.15 | -0.1 |
EPS (Diluted) | -0.23 | -0.24 | -0.16 | 1.70 | -0.26 | -0.27 | -0.18 | -0.16 | -0.19 | -0.15 | -0.1 |
EBITDA | -34.49M | -35.88M | -27.62M | 191.89M | -24M | -24.52M | -16.05M | -14.1M | -17.03M | -8.65M | -5.73M |
EBIT | n/a | n/a | -6.19B | 193.69M | -22.78M | -23.89M | -16.24M | -14.1M | -17.03M | -8.68M | -5.74M |
Depreciation & Amortization | 863.92K | 784.7K | -5.16M | 531.87K | 640.71K | 372.1K | 255.88K | -40.25K | 54K | 55.81K | 55.21K |